March 1, 1999Current Opinion in Cardiology
Current therapies for secondary prevention after myocardial infarction
Why the study?
Do secondary prevention therapies improve outcomes in patients after myocardial infarction?
Population
Patients with known coronary disease / post-myocardial infarction
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports secondary prevention post-MI; leaves open optimal implementation and adherence questions.
Key Points
- Summarize evidence-based secondary prevention strategies, encompassing pharmacologic therapies and lifestyle modifications, for patients with established coronary disease after myocardial infarction.
- Synthesized evidence from clinical trials evaluating secondary prevention strategies in patients with coronary heart disease.
- Evaluated pharmacologic treatments including antiplatelet agents, beta-blockers, lipid-lowering therapies, ACE inhibitors, and hormone replacement, alongside key lifestyle modifications.
- Secondary prevention therapies initiate substantial reductions in recurrent myocardial infarction, decrease revascularization requirements, and improve overall survival and quality of life.
- Guideline-directed medical therapy—comprising lipid-lowering drugs, antiplatelet agents, beta-blockers, and ACE inhibitors for systolic dysfunction—provides definitive benefit, whereas postmenopausal hormone replacement therapy shows no clinical benefit.
- Behavioral interventions, including smoking cessation, weight management, exercise, and dietary modification, serve as critical non-pharmacologic interventions to reduce secondary cardiovascular risk.
Structured PICO
Do secondary prevention therapies improve outcomes in patients after myocardial infarction?
P
Population
Patients with known coronary disease / post-myocardial infarction
I
Intervention
Secondary prevention therapies (lipid lowering therapy, antiplatelet agents, beta-blockers, hypertension control, ACE inhibitors, lifestyle modifications)
This review summarizes the established benefits of secondary prevention therapies, including medications and lifestyle modifications, for patients after myocardial infarction.
Cite This Study
Cannon et al. (1999) studied this question.